Evidence map›Paper›PMID 41271185›Full record

ArticleBrain, behavior, and immunity2026

The kynurenine pathway in pediatric "mild-to-moderate" traumatic brain injury: translational insights from a prospective human study and a large-animal model.

Harm J van der Horn, Koen Visser, Tracey V Wick, Samuel D Miller, Andrew P Gigliotti, Timothy B Meier, Harry van Goor, T Kent Teague, Claude van der Ley, Martijn van Faassen and 3 more

Abstract read
In one paragraph

Article in Brain, behavior, and immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Harm J van der HornDepartment of Neurology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. Electronic address: h.j.van.der.horn@umcg.nl.
Koen VisserDepartment of Neurology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Tracey V WickThe Mind Research Network/Lovelace Biomedical Research Institute, Albuquerque, NM, USA.
Samuel D MillerThe Mind Research Network/Lovelace Biomedical Research Institute, Albuquerque, NM, USA.
Andrew P GigliottiThe Mind Research Network/Lovelace Biomedical Research Institute, Albuquerque, NM, USA.
Timothy B MeierDepartment of Neurosurgery, Medical College of Wisconsin, Milwaukee, WI, USA; Department of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, Milwaukee, WI, USA; Department of Biomedical Engineering, Medical College of Wisconsin, Milwaukee, WI, USA.
Harry van GoorDivision of Pathology of the Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
T Kent TeagueDepartments of Surgery and Psychiatry, University of Oklahoma School of Community Medicine, Tulsa, OK, USA; Department of Biochemistry and Microbiology, Oklahoma State University Center for Health Sciences, Tulsa, OK, USA; Department of Pharmaceutical Sciences, University of Oklahoma College of Pharmacy- Oklahoma City, OK, USA.
Claude van der LeyDepartment of Laboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Martijn van FaassenDepartment of Laboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Ido P KemaDepartment of Laboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Joukje van der NaaltDepartment of Neurology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Andrew R MayerThe Mind Research Network/Lovelace Biomedical Research Institute, Albuquerque, NM, USA; Department of Neurology, University of New Mexico, Albuquerque, NM, USA; Department of Psychology, University of New Mexico, Albuquerque, NM, USA.

Funding

The Impact of Diffuse Mild Brain Injury on Clinical Outcomes in ChildrenR01NS098494 · NINDS · THE MIND RESEARCH NETWORK · PI Andrew Robert Mayer · 2016 to 2026
$7.6M
Pilot Project Program (PPP)P30GM122734 · NIGMS · THE MIND RESEARCH NETWORK · PI MAYER, ANDREW ROBERT · 2018 to 2022
$7.0M
Siemens MAGNETOM Prisma/Prisma fit upgradeS10OD025313 · OD · THE MIND RESEARCH NETWORK · PI MAYER, ANDREW ROBERT · 2018 to 2018
$1.5M
NIGMS NIH HHS P30 GM122734NIH HHS S10 OD025313NINDS NIH HHS R01 NS098494
6 · The paper itself

Abstract

Elucidating the biochemical pathways affected by pediatric traumatic brain injury (TBI) is essential for identifying informative blood-based biomarkers that may support future precision medicine and clinical trials. The kynurenine pathway (KP)-the primary route for tryptophan (Trp) degradation-represents a promising candidate due to its established link to (neuro)inflammation and TBI. The current study used liquid chromatography with tandem mass spectrometry to investigate KP metabolites in serum from 54 human patients with pediatric mild TBI (pmTBI; age 8-18 years) at ∼ 7 days and ∼ 4 months post-injury and 38 age- and sex-matched healthy controls (HC). The early temporal trajectories of KP metabolites were examined in more detail in serum samples collected from 33 juvenile swine with mild-to-moderate traumatic brain injury (mmTBI) at pre-injury baseline, and at 5 min, 35 min, 2.5 h, 24 h, and 7 days post-injury. Data from 10 sham animals were collected at equivalent time points. Interleukin 1 receptor antagonist (IL-1RA), IL-1β, IL-6, IL-10 and tumor necrosis factor (TNF) α were examined as measures of inflammation. In human pmTBI, significantly lower concentrations of Trp, 3-hydroxykynurenine (3HK), 3-hydroxyanthranilic acid (3HA), xanthurenic acid (XA) and picolinic acid (PA) were observed relative to HC, with stronger effects at 4 months relative to 7 days post-injury. Lower concentrations of Trp, 3HA, and XA at 4 months were associated with persistent post-concussive symptoms (PCS). As predicted, findings for inflammatory markers were null at these time points. In the large-animal model, an increased response of the anti-inflammatory IL-1RA was found at 2.5 h post-injury in mmTBI relative to sham animals, without any group differences in KP metabolites or other inflammatory markers. Both animal groups showed prominent temporal metabolite changes, including increased Trp at 2.5 h and decreased PA up to 24 h post-injury, likely reflecting cumulative effects of isoflurane anesthesia and associated dampening of pro-inflammatory responses. Altogether, our findings indicate long-lasting effects of pmTBI on the KP in humans. Disparate profiles were observed for human and large-animal injuries, which highlights the importance of incorporating clinically relevant biomarkers in preclinical studies to improve the translation of preclinical findings into successful future clinical trials.

Indexed as

Brain ConcussionBrain Injuries, TraumaticKynurenineAdolescentAnimalsBiomarkersChildDisease Models, AnimalFemaleHumansInflammationMaleProspective StudiesSwineTryptophanBiomarkersKynurenineTryptophanAnimal studyBiomarkersConcussionInflammationPathophysiology

Identifiers

PMID41271185
PMCPMC13344367

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.